![Rolf M. Zinkernagel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rolf M. Zinkernagel
Plus aucun poste en cours
Profil
Rolf M.
Zinkernagel is the founder of Telormedix SA (founded in 2007), HOOKIPA Pharma, Inc. (founded in 2011), and Hookipa Biotech GmbH (founded in 2011).
He also held former positions at Novartis AG as an Independent Non-Executive Director from 1999 to 2014, Cytos Biotechnology AG as a Director in 2003, the University of Zurich as a Professor & Director in 2008, Novartis Institute for Functional Genomics, Inc. as a Director, Aravis AG as a Venture & Scientific Partner, and the International Union of Immunological Societies as a Vice President.
Dr. Zinkernagel obtained his doctorate degree from the University of Basel in 1970.
Anciens postes connus de Rolf M. Zinkernagel
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Directeur/Membre du Conseil | 25/02/2014 |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Private Equity Investor | 31/12/2013 |
International Union of Immunological Societies | Corporate Officer/Principal | - |
University of Zurich
 University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Directeur/Membre du Conseil | 01/01/2008 |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Directeur/Membre du Conseil | 01/04/2003 |
Formation de Rolf M. Zinkernagel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
91
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Commercial Services |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aravis AG
Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Finance |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts research related to biotechnology and medicine | Commercial Services |
Telormedix SA
 Telormedix SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases | Health Technology |
International Union of Immunological Societies | |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Develops new generation prophylactic and therapeutic vaccines | Health Technology |
HOOKIPA Pharma, Inc.
 HOOKIPA Pharma, Inc. BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company which develops pharmaceutical products for immunotherapeutics targeting infectious diseases and cancers | Health Technology |
Choisissez Zonebourse 
